Combined schedule of fludarabine and alemtuzumab followed by maintenance with low-dose alemtuzumab is effective for patients with progressive B-cell chronic lymphocytic leukemia.

被引：0
|
作者：
Kowal, M
Nowak, W
Nowaczynska, A
Dmoszynska, A
Skotnicki, AB
机构：
[1] Jagiellonian Univ, Fac Med, Dept Haematol, Krakow, Poland
[2] Med Univ Lublin, Dept Haematooncol & Bone Marrow Transplantat, Lublin, Poland
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5048
引用
收藏
页码：343B / 344B
页数：2
相关论文
共 50 条
  • [31] Combined fludarabine, cyclophosphamide, and alemtuzumab (FCC), an active regimen for treated patients with chronic lymphocytic leukemia (CLL)
    Montillo, Marco
    Miqueleiz, Sara
    Tedeschi, Alessandra
    Ricci, Francesca
    Vismara, Eleonora
    Ciapanna, Denis
    Petrizzi, Valeria Belsito
    Crugnola, Monica
    Spriano, Mauro
    Uziel, Lilj
    De Blasio, Angelo
    Spedini, Pierangelo
    Morra, Enrica
    BLOOD, 2007, 110 (11) : 922A - 922A
  • [32] Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia
    Montillo, M
    Tedeschi, A
    Miqueleiz, S
    Veronese, S
    Cairoli, R
    Intropido, L
    Ricci, F
    Colosimo, A
    Scarpati, B
    Montagna, M
    Nichelatti, M
    Regazzi, M
    Morra, E
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2337 - 2342
  • [33] Alemtuzumab (Campath®, MabCampath®) consolidation after fludarabine phosphate and cyclophosphamide second-line chemotherapy for progressive chronic lymphocytic leukemia.
    Vitolo, U
    Orsucci, L
    di Celle, PF
    Bergui, L
    Boccomini, C
    Botto, B
    Godio, L
    Pregno, P
    Tarella, C
    Gallo, E
    BLOOD, 2003, 102 (11) : 356B - 356B
  • [34] Fludarabine and alemtuzumab versus fludarabine and rituximab in the treatment of relapsed B-cell chronic lymphocytic leukemia: Results from a phase II study.
    Gribben, J
    Stephans, K
    Marshal, B
    BLOOD, 2005, 106 (11) : 343B - 343B
  • [35] Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia
    Jeanette Lundin
    Claes Karlsson
    Fredrik Celsing
    Medical Oncology, 2006, 23 (1) : 137 - 139
  • [36] Treatment of severe autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab
    B Royer
    I Vaida
    A Etienne
    R Garidi
    G Damaj
    J P Marolleau
    Leukemia, 2007, 21 : 1841 - 1842
  • [37] Treatment of severe autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab
    Royer, B.
    Vaida, I.
    Etienne, A.
    Garidi, R.
    Damaj, G.
    Marolleau, J. P.
    LEUKEMIA, 2007, 21 (08) : 1841 - 1842
  • [38] A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia
    Cortelezzi, A
    Pasquini, MC
    Sarina, B
    Bertani, G
    Grifoni, F
    Colombi, M
    Deliliers, GL
    HAEMATOLOGICA, 2005, 90 (03) : 410 - 412
  • [39] Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia
    Lundin, J
    Karlsson, C
    Celsing, F
    MEDICAL ONCOLOGY, 2006, 23 (01) : 137 - 139
  • [40] Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sezary syndrome
    Gibbs, SDJ
    Herbert, KE
    McCormack, C
    Seymour, JF
    Prince, HM
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 73 (06) : 447 - 449
12345